First Heartland Consultants Inc. Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

First Heartland Consultants Inc. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 36.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,475 shares of the biopharmaceutical company’s stock after purchasing an additional 1,464 shares during the quarter. First Heartland Consultants Inc.’s holdings in Gilead Sciences were worth $376,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Institute for Wealth Management LLC. lifted its stake in Gilead Sciences by 1.9% during the second quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 142 shares during the last quarter. First Affirmative Financial Network lifted its stake in Gilead Sciences by 3.5% in the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 147 shares during the last quarter. Rathbones Group PLC lifted its stake in Gilead Sciences by 3.7% in the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 150 shares during the last quarter. MCF Advisors LLC lifted its stake in Gilead Sciences by 2.1% in the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 152 shares during the last quarter. Finally, Westside Investment Management Inc. lifted its stake in Gilead Sciences by 0.6% in the second quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company’s stock valued at $1,826,000 after buying an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GILD. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Truist Financial boosted their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Barclays reduced their price objective on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. BMO Capital Markets boosted their target price on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Maxim Group dropped their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $81.94.

Gilead Sciences Trading Up 0.3 %

Shares of GILD stock opened at $76.96 on Tuesday. The business’s fifty day moving average price is $72.13 and its 200 day moving average price is $70.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The firm has a market capitalization of $95.88 billion, a PE ratio of 213.78, a P/E/G ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 4.00%. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.